36 Heart Attack Clinical Trials in New Haven, CT (2026)

Q: How do I join a clinical trial in New Haven?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the New Haven research site will contact you.

Recruiting Heart Attack Studies in New Haven

NCT06289985Recruiting

StrokeNet Thrombectomy Endovascular Platform

STEP is a Randomized, Multifactorial, Adaptive Platform trial that seeks to optimize the care of patients with acute ischemic stroke (AIS) due to large (LVO) or medium vessel occlusions (MVO)....

New Haven, CTNA1,600 participantsMedical University of South Carolina

View Study Details

NCT07007312Recruiting

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target ...

New Haven, CTPHASE31,300 participantsKura Oncology, Inc.

View Study Details

NCT03242642Recruiting

Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device....

New Haven, CTNA1,056 participantsMedtronic Cardiovascular

View Study Details

NCT07018700Recruiting

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

In this clinical trial, participants with episodic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine d...

New Haven, CTPHASE3990 participantsMerz Therapeutics GmbH

View Study Details

NCT07018713Recruiting

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

In this clinical trial, participants with chronic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine da...

New Haven, CTPHASE3780 participantsMerz Therapeutics GmbH

View Study Details

NCT06943872Recruiting

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia...

New Haven, CTPHASE3630 participantsBeiGene

View Study Details

NCT05378347Recruiting

Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial

The purpose of this trial is to generate clinical evidence related to key performance outcomes of Endurant II/IIs Stent Graft Systems verses Gore Excluder / Excluder Conformable AAA Endoprosthesis in ...

New Haven, CTNA600 participantsMedtronic Cardiovascular

View Study Details

NCT05164172Recruiting

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine....

New Haven, CTPHASE3600 participantsH. Lundbeck A/S

View Study Details

NCT05131022Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies....

New Haven, CTPHASE1572 participantsNurix Therapeutics, Inc.

View Study Details

NCT05735184Recruiting

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will inve...

New Haven, CTPHASE1420 participantsKura Oncology, Inc.

View Study Details

NCT01790152Recruiting

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory ...

New Haven, CT420 participantsChildren's Oncology Group

View Study Details

NCT05554406Recruiting

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with...

New Haven, CTPHASE2335 participantsNational Cancer Institute (NCI)

View Study Details

NCT05702645Recruiting

A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

This study attempts to learn more about the health of persons with Down syndrome after treatment for acute leukemia. Children with Down syndrome are at increased risk for side effects during treatment...

New Haven, CT330 participantsChildren's Oncology Group

View Study Details

NCT04787042Recruiting

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatme...

New Haven, CTPHASE1316 participantsSimcha IL-18, Inc.

View Study Details

NCT04256317Recruiting

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms and a Phase 1 Combination Therapy arm Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) us...

New Haven, CTPHASE2316 participantsTaiho Oncology, Inc.

View Study Details

NCT05948566Recruiting

Strategy for Improving Stroke Treatment Response

SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alp...

New Haven, CTPHASE2300 participantsTranslational Sciences, Inc.

View Study Details

NCT06456346Recruiting

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (ET) participants for whom cytoreduct...

New Haven, CTPHASE3300 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06747117Recruiting

A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus With the Indigo™ Aspiration System (STRIDE II)

The primary objective of this study is to collect and evaluate clinical evidence supporting the safety and performance of the Indigo™ Aspiration System in a patient population with lower extremity acu...

New Haven, CT300 participantsPenumbra Inc.

View Study Details

NCT06880770Recruiting

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

This study will evaluate the efficacy and safety of plozasiran in approximately 140 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP)...

New Haven, CTPHASE3288 participantsArrowhead Pharmaceuticals

View Study Details

NCT04965675Recruiting

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine....

New Haven, CTPHASE3285 participantsH. Lundbeck A/S

View Study Details

NCT05869955Recruiting

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1)....

New Haven, CTPHASE1270 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT03850574Recruiting

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelod...

New Haven, CTPHASE1240 participantsAptose Biosciences Inc.

View Study Details

NCT05475925Recruiting

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular ...

New Haven, CTPHASE1200 participantsDren Bio

View Study Details

NCT05650229Recruiting

Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

The primary objective of the FALCON study is to evaluate the efficacy of KL1333 on selected disease manifestations of primary mitochondrial disease (PMD) following 48 weeks of treatment. This objectiv...

New Haven, CTPHASE2180 participantsAbliva AB

View Study Details

NCT06428019Recruiting

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutini...

New Haven, CTPHASE3170 participantsAbbVie

View Study Details

NCT06950385Recruiting

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compa...

New Haven, CTPHASE3168 participantsRapamycin Holdings Inc.

View Study Details

NCT05756257Recruiting

Blood Pressure Variability and Ischemic Stroke Outcome

The goal of this observational study is to evaluate the role of blood pressure (BPV) variability in patients suffering from acute ischemic stroke. The main questions it aims to answer are: 1. To dete...

New Haven, CT150 participantsYale University

View Study Details

NCT05183035Recruiting

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults wit...

New Haven, CTPHASE3130 participantsPedAL BCU, LLC

View Study Details

NCT07086976Recruiting

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

This is a parallel-group, Phase 3, double-blind, 2-arm study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb response (DHR) compared with placebo in approx...

New Haven, CTPHASE390 participantsSanofi

View Study Details

NCT06582615Recruiting

Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer

The goal of this randomized clinical trial is to learn if a healthy eating pattern called the MIND eating plan can reduce cancer-related cognitive impairment (commonly called "chemobrain") and other s...

New Haven, CTNA60 participantsOhio State University Comprehensive Cancer Center

View Study Details

NCT07228429Recruiting

Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography Images

The main purpose of this study is to develop sensitive radiographic measurement techniques that can be used as outcome measures along with patient-reported outcome instruments in clinical trials of ca...

New Haven, CT56 participantsYale University

View Study Details

NCT07080385Recruiting

Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)

The overall objective of this study is to evaluate the pharmacokinetics (PK), efficacy, and safety of encaleret in pediatric participants from birth to 17 years of age with ADH1....

New Haven, CTPHASE228 participantsCalcilytix Therapeutics, Inc., a BridgeBio company

View Study Details

NCT06121297Recruiting

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus...

New Haven, CTPHASE128 participantsCabaletta Bio

View Study Details

NCT06525636Recruiting

A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia

A first-in-human study of KK8123 in adults with X-linked hypophosphatemia....

New Haven, CTPHASE124 participantsKyowa Kirin Co., Ltd.

View Study Details

NCT07161037Recruiting

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407....

New Haven, CTPHASE224 participantsVertex Pharmaceuticals Incorporated

View Study Details

NCT06328777Recruiting

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis...

New Haven, CTPHASE112 participantsCabaletta Bio

View Study Details

About Heart Attack Clinical Trials in New Haven

A heart attack (myocardial infarction) occurs when blood flow to part of the heart muscle is blocked, usually by a blood clot. It is a medical emergency requiring immediate treatment. Long-term management includes medications, lifestyle changes, and cardiac rehabilitation.

There are currently 36 heart attack clinical trials recruiting participants in New Haven, CT. These studies are seeking a combined 13,568 participants. Research is being sponsored by Medical University of South Carolina, Kura Oncology, Inc., Medtronic Cardiovascular and 26 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Heart Attack Clinical Trials in New Haven — FAQ

Are there heart attack clinical trials in New Haven?

Yes, there are 36 heart attack clinical trials currently recruiting in New Haven, CT. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New Haven?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New Haven research site will contact you about next steps.

Are clinical trials in New Haven free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New Haven studies also compensate for your time and travel.

What heart attack treatments are being tested?

The 36 active trials in New Haven are testing new therapies including novel drugs, biologics, and treatment approaches for heart attack.

Data updated July 17, 2026 from ClinicalTrials.gov